Review article · 2022
Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy
Drug Discovery Today, 28(1), 103434 · Published 8 November 2022 · DOI 10.1016/j.drudis.2022.103434
In brief
“Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy” is a 2022 review article by Ahmed O. Elzoghby and 3 co-authors, published in Drug Discovery Today. OpenAlex counts 11 citations as of 21 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 11
- Most cited in
- 2024 (6)
- Field-weighted impact
- 0.27
- References
- 57
- Authors
- 4
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Elzoghby, A. O., Ferrone, C. R., Ferrone, S., & Nasr, M. L. (2022). Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy. Drug Discovery Today, 28(1), 103434. https://doi.org/10.1016/j.drudis.2022.103434
MLA 9
Elzoghby, Ahmed O., et al. “Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy.” Drug Discovery Today, vol. 28, no. 1, 2022, p. 103434. https://doi.org/10.1016/j.drudis.2022.103434.
Chicago
Elzoghby, Ahmed O., Cristina R. Ferrone, Soldano Ferrone, and Mahmoud Lotfi Nasr. 2022. “Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy.” Drug Discovery Today 28 (1): 103434. https://doi.org/10.1016/j.drudis.2022.103434.
Harvard
Elzoghby, A. O. et al. (2022) ‘Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy’, Drug Discovery Today, 28(1), p. 103434. doi:10.1016/j.drudis.2022.103434.
IEEE
A. O. Elzoghby, C. R. Ferrone, S. Ferrone, and M. L. Nasr, “Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy,” Drug Discovery Today, vol. 28, no. 1, p. 103434, 2022, doi: 10.1016/j.drudis.2022.103434.
BibTeX
@article{elzoghby2022engineered,
title = {{Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy}},
author = {Elzoghby, Ahmed O. and Ferrone, Cristina R. and Ferrone, Soldano and Nasr, Mahmoud Lotfi},
journal = {Drug Discovery Today},
year = {2022},
volume = {28},
number = {1},
pages = {103434},
doi = {10.1016/j.drudis.2022.103434},
url = {https://doi.org/10.1016/j.drudis.2022.103434}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 2 | |
| 2024 | 6 | |
| 2025 | 1 | |
| 2026 | 2 |
Its field-weighted citation impact is 0.27: it has been cited 0.27 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- pancreatic cancer
- nanomedicine
- immunotherapy resistance
- immune checkpoint inhibitors
- cancer-associated fibroblasts
- dendritic cells
- tumor microenvironment
- cytotoxic T lymphocytes
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Elzoghby, A. O., Ferrone, C. R., Ferrone, S., & Nasr, M. L. (2022). Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy. Drug Discovery Today, 28(1), 103434. https://doi.org/10.1016/j.drudis.2022.103434
How many times has this paper been cited?
11 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Ahmed O. Elzoghby, Cristina R. Ferrone, Soldano Ferrone, Mahmoud Lotfi Nasr.
What is the DOI of this paper?
10.1016/j.drudis.2022.103434, permanently at https://doi.org/10.1016/j.drudis.2022.103434. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.